Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital

Risk of second primary malignancy was assessed in follow-up to June 1991 of 1039 patients first treated for Hodgkin's disease at the Royal Marsden Hospital during 1963-91. A total of 77 second malignancies occurred. There were significantly raised risks of stomach [standardized incidence ratio...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1997-01, Vol.75 (1), p.116-123
Main Authors: Swerdlow, AJ, Barber, JA, Horwich, A, Cunningham, D, Milan, S, Omar, RZ
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cancer Research
Child
Child, Preschool
Chlorambucil - therapeutic use
Drug Resistance
Epidemiology
Female
Hematologic and hematopoietic diseases
Hodgkin Disease - complications
Hodgkin Disease - therapy
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Mechlorethamine - therapeutic use
Medical sciences
Middle Aged
Molecular Medicine
Neoplasms, Second Primary - epidemiology
Oncology
Prednisone - therapeutic use
Procarbazine - therapeutic use
Risk
Risk Factors
Vinblastine - therapeutic use
Vincristine - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Risk of second primary malignancy was assessed in follow-up to June 1991 of 1039 patients first treated for Hodgkin's disease at the Royal Marsden Hospital during 1963-91. A total of 77 second malignancies occurred. There were significantly raised risks of stomach [standardized incidence ratio (SIR)=4.0], lung (SIR=3.8), bone (SIR=26.5), soft tissue (SIR=16.9) and non-melanoma skin (SIR=3.9) cancers, non-Hodgkin's lymphoma (SIR=4.6), and acute and non-lymphocytic leukaemia (SIR=31.3), with a relative risk of 3.3 for all second cancers other than non-melanoma skin cancer. Solid cancer risk was raised to a similar extent in patients treated only with radiotherapy (SIR=2.6, P
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1997.19